Merck to Sell CDMO Business at Five US Sites to Lonza
Merck has announced plans to divest its Contract Development and Manufacturing Organization (CDMO) business across five sites in the United States to Lonza. This strategic move will transfer operations and assets related to pharmaceutical development and manufacturing from Merck to Lonza, expanding Lonza's footprint in the US pharmaceutical sector.
European Pharmaceutical Review·




